ClinicalTrials.gov
public full text
Public Domain
The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment
Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD). In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Associations among sleep quality, cognitive decline, and Alzheimer's disease pathology in older adults: A longitudinal study.#265258
- Melatonin for Delirium Prophylaxis#902517
- Association of sleep duration with Alzheimer's disease and cognition.#354869
- Improving Well-being by Improving Memory for Treatment for Sleep and Circadian Dysfunction#1104282
- Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI#901676
Record · ID 888236
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive